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Introduction
The integrins are a family of αβ heterodimeric receptors
that mediate dynamic linkages between extracellular adhe-
sion molecules and the intracellular actin cytoskeleton.
Integrins are expressed by all multicellular animals. In
mammals, 18 α-subunit genes and eight β-subunit genes
encode polypeptides that combine to form 24 different
receptors. Both integrin subunits are noncovalently asso-
ciated, type I transmembrane proteins with large extracel-
lular domains and short cytoplasmic domains of
700–1100 and 30–50 residues, respectively.
Thousands of studies have investigated the molecular, cel-
lular and organismal basis of integrin function. Gene dele-
tion has demonstrated essential roles for almost all
integrins, with the defects suggesting widespread contri-
butions to the maintenance of tissue integrity and the pro-
motion of cellular migration. Integrin–ligand interactions
are now considered to provide physical support for cells
to maintain cohesion, to permit the generation of traction
forces to enable movement, and to organise signalling
complexes to modulate differentiation and cell fate.
Animal model studies have also shown integrins to con-
tribute to the progression of many common diseases, and
have implicated them as potential therapeutic targets. The
use of anti-integrin mAbs and ligand mimetic peptides has
validated this suggestion for inflammatory, neoplastic, trau-
matic and infectious conditions. There is thus intense
interest in determining the molecular basis of integrin func-
tion to identify approaches for regulating integrin function
in disease. The recent publication of an integrin crystal
structure promises to aid this process, most obviously by
defining the ligand-binding pocket but also by suggesting
mechanisms of receptor activation. These topics form the
basis of this review.
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Chapter summary
Integrin receptors transduce bidirectional signals between extracellular adhesion molecules and
intracellular cytoskeletal and signalling molecules. The structural basis of integrin signalling is unknown,
but the recent publication of the first crystal structure of the extracellular domain of integrin αVβ3 has
provided a number of insights. In this review, previous structure–function analyses of integrins that
have employed biochemical and molecular biological approaches are placed in the context of the
crystal structure, and novel routes to the development of integrin antagonists are discussed.
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An integrin crystal structure
The first three-dimensional structure of the extracellular
domain of an integrin was published in October 2001, a
decade and a half after the family was first defined [1]. The
team responsible for this landmark study was led by Amin
Arnaout (Massachusetts General Hospital, Boston, MA,
USA), and comprised crystallographers at the Massachu-
setts General Hospital and the Argonne National Labora-
tory, IL, USA, and protein chemists at Merck KGaA in
Darmstadt, Germany. The integrin selected for the work
was αVβ3, a promiscuous receptor that binds vitronectin,
fibronectin, von Willebrand factor and other extracellular
matrix ligands. Both subunits of the heterodimer were
expressed as full-length, soluble, glycosylated constructs in
insect cells, and were crystallised in the presence of Ca2+.
The overall shape of the crystallised conformer (resolved
to 3.1 Å) is that of a large ‘head’ on two ‘legs’, with the
N-termini of both subunits forming the head and the
C-termini forming the legs (Fig. 1). Similar images of inte-
grins had been obtained previously from rotary-shadowed
and negatively stained specimens analysed by electron
microscopy [2,3], and it had been correctly predicted that
the legs would be the sites of subunit insertion into the
plasma membrane. Furthermore, rotary-shadowed images
of the platelet integrin αIIbβ3 bound to its major ligand fib-
rinogen revealed a highly specific interaction of the head
of the integrin with the distal end of the fibrinogen
hexamer, suggesting that the head contains the ligand-
binding domain [4]. One major difference between the
results from these two different structure-determination
approaches, however, is the degree of extension of the
legs. Both legs are bent in the crystal structure, whereas
most electron microscopy images possess straightened
legs. The relevance of these differences for receptor acti-
vation is discussed later.
In the crystal structure, the head of the integrin contains a
seven-bladed  β-propeller structure from the α-subunit
(comprising seven ~60-amino-acid N-terminal repeats)
and a von Willebrand factor A-domain from the β-subunit
(termed the βA-domain; Fig. 1). The presence of these two
folds had been predicted previously [5,6]. The βA-domain
is anchored to the upper face of the β-propeller, with an
arginine residue in a 310 helical segment of the βA-domain
(between βD and α5) linked to a hydrophobic ‘cage’ in the
central shaft of the β-propeller. The remainder of the head
composes an immunoglobulin module into which the βA-
domain is inserted.
The α-subunit leg of the integrin contains three large β-
sandwich domains. Between the so-called ‘thigh’ domain
and the first of two ‘calf’ domains is a highly flexible ‘knee’
(or ‘genu’), which is the site of the bend in the crystal
structure. The more C-terminal domain of the calf domains
contains a site that is cleaved post-translationally to yield
an N-terminal heavy chain and a C-terminal light chain,
although the atomic detail is not visible in the structure.
The β-subunit leg contains a plexin–semaphorin–integrin
(PSI) domain, four epidermal growth factor-like repeats
and a novel cystatin-like fold. The 50-residue PSI domain
was also not visible in the structure, but it has been pre-
dicted to possess α-helical character [7]. The β-subunit
knee region, formed from the conjunction of the hybrid
domain, two epidermal growth factor repeats, and the PSI
domain, is also bent.
It has previously been shown that truncated αIIb con-
structs that ended before N-terminal repeats 5, 6 or 7 all
associated with their partner subunit β3 [8], and that
limited proteolysis of αIIbβ3 bound to a ligand affinity
matrix produced a 55/85 kDa heterodimer containing the
N-termini of both subunits that reacted with dimer-specific
antibodies [9]. The suggestion from these studies that the
head region of the integrin contains the major sites of
intersubunit association and dimerisation was therefore
confirmed by the crystal structure.
Figure 1
Crystal structure of integrin αVβ3 showing the dimer and individual
subunits [1]. The domains that make up each integrin subunit are
shown. Secondary structure elements are shown as red α-helices or
cyan β-strands/ribbons. Blue circles represent the six cation-binding
sites. The plexin–semaphorin–integrin domain and two of the four
epidermal growth factor (EGF) repeats in the β-subunit are not visible
in the structure.S71
Similarly, the spatial relationship between different sub-
domains of integrin subunits had been partially determined
by protein chemistry. For example, cyanogen bromide
cleavage of αIIbβ3, followed by amino acid and N-terminal
sequence analysis of the isolated fragments, permitted
localisation of all S–S bonds, including a long-range bond
joining the N-terminus to the region just after the hybrid
domain (C5–C435) [10,11]. Although this bond is not
visible in the crystal structure, it is clear that the PSI
domain is positioned close enough to the junction
between the hybrid domain and the first epidermal growth
factor repeat to form the link. The close association of the
N-terminal regions of both integrin subunits explains their
mutual dependence for folding as assessed using confor-
mation-dependent mAbs as probes [12,13]. mAbs that
recognise only the α-subunit β-propeller or the βA-domain
recognise heterodimeric integrin, while mAbs that are
directed against the αA-domain or the legs of either
subunit react with their respective monomer.
Integrins actually fall into two subfamilies based on the
presence or absence of a 200-amino-acid module in the
α-subunit. This module, which is present in nine α-sub-
units, shares sequence homology with a von Willebrand
factor A-domain, and is inserted between the second and
third N-terminal repeats. Although αV lacks an A-domain,
the crystal structure does suggest a potential location for
the inserted αA-domain, at the side and the top of the β-
propeller (see Fig. 3 later).
Prior to the αVβ3 structure, the only region of an integrin
for which tertiary structure information was available was
the αA-domain, as these domains fold independently and
can be expressed in recombinant form. Crystal structures
from four α-subunits (α1,  α2,  αL and αM) have been
solved, the first being the αM A-domain [14]. The protein
was found to adopt a classical αβ Rossmann fold in which
the core of the module was made up of five parallel β-
strands and one antiparallel β-strand, decorated peripher-
ally by a series of seven α-helices (Fig. 2). A Mg2+ ion was
located at one end of the module, where it was coordi-
nated in an octahedral geometry by residues from three
different loops and from a glutamate side chain from
another A-domain molecule adjacent in the crystal lattice.
This latter interaction was suggested to mimic a
ligand–receptor complex [14]. Further crystal forms of the
αM and αL A-domains were then reported in which water
completed the metal coordination sphere and there was
no equivalent of the glutamate ligand [15]. This raised
doubts about the relevance of the cation-dependent differ-
ence in the A-domain conformation, as discussed later.
The remainder of this review addresses two key questions
posed by the integrin structure: how do ligands bind to
the two subfamilies of integrin receptors, and how is
receptor activation achieved in both types of integrin?
Ligand-binding sites
The definition of the ligand-binding pocket of an integrin is
important because it will generate insights into the relative
contributions of different regions of receptor and ligand to
the specific binding event. In addition, it will inform the
process of drug design by identifying the receptor
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Figure 2
Comparison of the crystal structure of the α2 A-domain either (a) free
or (b) complexed with a collagenous peptide [41,47]. Secondary
structure elements are shown as red α-helices or cyan β-
strands/ribbons. Spheres represent the divalent cation coordinated by
the metal ion-dependent adhesion site (MIDAS) motif. The α7 helix is
shown in pink. Note the difference in position of α7 in the two
structures and the fact that the construct used in (b) contained a
truncated α7 helix. The collagen glutamate residue that coordinates
the MIDAS cation is shown in green. The MIDAS cation is shown as a
blue circle.S72
residues that participate in contacts with ligand. Ulti-
mately, the solution of the tertiary structure of an
integrin–ligand complex is needed to provide this informa-
tion but, in the current absence of such structures, data
from a number of experimental approaches have sug-
gested the sites within integrins that bind ligand. This
information can now be mapped onto the αVβ3 structure.
Non-α αA-domain-containing integrins
Integrin chimeras
Inter-integrin chimeras have been employed to pinpoint
sites determining ligand specificity. Subtle differences in the
ligand-binding specificity of the related α5- and αV-subunits
were recently exploited to pinpoint the regions of the α-sub-
units responsible, using a gain-of-function approach. The α5
subunit preferentially recognises the so-called ‘synergy’ site
in type III repeat 9 of its ligand fibronectin, binds strongly to
RGD peptides containing a C-terminal tryptophan residue
(e.g. RGDGW), and binds specifically to the peptide
RRETAWA. The high sequence identity (~50%) between
α5 and αV permitted the construction of chimeras bearing
hybrid native structures. It was reported that repeats 2 and
3 of α5, when introduced into αV, were sufficient to endow
αV with the epitopes of all function-blocking anti-α5 mAbs
and with the ligand-binding specificity of α5 [16].
The exchange of putative loops between the two subunits,
based on the β-propeller prediction that turned out to be
correct, led to the identification of a single residue, α5
W157, which was sufficient to convert αV into a receptor
that strongly recognised RGDGW and RRETAWA [17].
This finding suggests that W157 (located in the loop con-
necting repeats 2 and 3) is close to the RGD-binding site
on β1. Additional studies that measured the loss of ligand-
binding activity in chimeras, while not as convincing, pro-
duced similar conclusions.
Similar analyses of the integrin β-subunit have highlighted
the importance of the βA-domain. For example, replace-
ment of β1 C187TSEQNC with β3 CYDMKTTC con-
verted the ligand specificity of αVβ1 to be more similar to
αVβ3 (i.e. increased binding of fibrinogen, von Willebrand
factor and vitronectin) [18]. This sequence is located in a
large disulfide-bonded loop between βB and βC adjacent
to the cation-binding site in the βA-domain (Fig. 3).
Cross-linking
The discovery that many integrin ligands employ short,
acidic peptide motifs (such as RGD and LDV) as key
receptor-binding sequences [19] led to the use of chemi-
cal cross-linking as a means of pinpointing ligand-binding
sites. In the earliest studies, RGD was found to cross-link
primarily to the β3 A-domain residues 109–171 or
residues 61–203 [20,21], and subsequently a 1:1 stoi-
chiometric  β3 (residues 119–131)–RGD complex was
detected by mass spectroscopy [22].
Synthetic peptides mimicking putative ligand-binding sites
in integrins have been synthesised and tested for their
ability to bind ligand directly and to inhibit ligand binding to
native integrin. The most definitive study identified two over-
lapping peptides encompassing residues 204–229 of the
β3 A-domain that blocked the binding of fibrinogen to puri-
fied  αIIbβ3 [23]. The minimal active peptide was subse-
quently determined to be RNRDA in the α2–α3 loop [24].
Cross-linking has been performed with more potent pep-
tidic ligands, the higher affinity of which might be expected
to improve specificity. An LDV-based small molecule
inhibitor of α4β1 (BIO-1494) that contained a single reac-
tive amino group was cross-linked to purified or cell-
expressed  α4β1 [25]. The site of cross-linking was
localised by CNBr peptide mapping to β1 (residues
130–146), a region that contains the putative metal
binding site in the βA-domain. Similarly, tagged photo-
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Figure 3
Enlarged view of the potential ligand-binding pocket of integrin αVβ3.
The loops on the top of the α-subunit β-propeller implicated in ligand
binding are coloured: purple, the 4–1 loop connecting repeats 1–2;
orange, the 4–1 loop connecting repeats 2–3; pink, the 4–1 loop
connecting repeats 3–4; green, the 2–3 loop in repeat 2; yellow, the
2–3 loop in repeat 3. The potential site for binding the fibronectin
synergy sequence in α5β1, the β-strand 4 in repeat 3, is coloured blue
(left side of β-propeller). The CYDMKTTC peptide sequence
determining ligand specificity in β3 is coloured blue (top of βA-
domain). Cations in the αVβ3 crystal structure are shown as blue
spheres. The potential site of the metal ion-dependent adhesion site
(MIDAS) cation is shown as a green circle. The site of insertion of an
αA-domain would be in the orange loop of the β-propeller. The solid
double arrow shows the possible orientation of ligand relative to the
integrin, with dashed lines indicating speculative contacts with the
MIDAS cation and β-strand 4 in repeat 3.S73
reactive cyclic RGD-containing ligands for αIIbβ3 cross-
linked specifically to β3 in a cation-dependent manner
[26]. Enzymatic and chemical digestions of the radiola-
belled conjugate identified β3 (residues 99–118) as the
RGD contact site. The similarity between the data gener-
ated for LDV and RGD ligands supports the notion of a
common ligand-binding pocket for both motifs.
Mutagenesis and mAb epitope mapping
A key assumption underlying the use of epitope mapping
to identify ligand-binding sites was that function-blocking
mAbs act as competitive inhibitors. This now appears not
to be the case, with many anti-integrin mAbs having been
shown to function via allosteric mechanisms. The first indi-
cation of allosteric inhibition by an anti-integrin mAb came
from studies of the binding of a fibronectin fragment and
GRGDS peptide to α5β1 [27]. Ligand binding caused a
dramatic attenuation of the mAb 13 epitope, and the anti-
body preferentially recognised the unoccupied conforma-
tion of the integrin. This suggested that the antibody
inhibits ligand binding either by stabilising the unoccupied
state of the receptor or by preventing a conformational
change necessary for ligand occupancy. Similar results
have subsequently been obtained for many other anti-
integrin mAbs.
If anti-functional mAbs recognise integrin sites whose
structures are perturbed as a consequence of ligand
engagement, then specific sites within the ligand must be
responsible for triggering the conformational changes.
Using a series of recombinant fragments of fibronectin
containing mutations in either the RGD or synergy active
sites, the topology of ligand engagement to α5β1 was
determined [28]. RGD preferentially perturbed anti-β1
mAb recognition of the integrin, while fragments mutated
in the synergy site were unable to block binding of an anti-
α5 mAb (P1D6) that mapped to L212 of β1 (β-strand 4 of
repeat 3; Fig. 3). Further analysis of the links between
ligand binding and mAb binding, in conjunction with the
αVβ3 crystal structure, should allow the ligand to be posi-
tioned relative to the integrin.
Following the identification of regions within the α-subunit
β-propeller and the β-subunit A-domain as putative regions
for ligand binding, site-directed mutagenesis has been
employed as a method to pinpoint residues contacting the
ligand (see [29] for a review). In the α-subunit β-propeller,
ligand binding is perturbed by mutations in loops that are
predicted to lie on the ‘top’ of the domain, on the opposite
face to the EF-hand-like sequences. In particular, the intra-
repeat 2–3 loop of repeat 3 and the inter-repeat 4–1 loops
joining repeats 1–2, 2–3 and 3–4 contain the key residues
in all integrins tested to date (Fig. 3).
Similar results have come from mAb epitope mapping,
where again the 4–1 loops joining repeats 1–2, 2–3 and
3–4 tend to contain key residues. In the integrin β-sub-
units, virtually all inhibitory mAbs map to the βA-domain,
and mutation of cation-coordinating residues in the βA-
domain abolishes ligand binding in all integrins tested.
Alteration of residues within the α3–α4 loop and α4 helix
(which are located on the same face as the divalent
cation) also appear to be important for several integrins. In
a recent study mapping fibrinogen binding sites in αIIbβ3,
most of the critical residues were located at the edge of
the upper face of the propeller, and several critical
residues are located on the side of the propeller domain,
in a region corresponding to the anti-α5 mAb P1D6
epitope [30].
Taken together, these data support a model in which the
RGD or LDV ligand motif interacts with the cation-binding
site in the βA-domain and additional contacts are made
with the side of the α-subunit β-propeller (Fig. 3). The criti-
cal requirement for a carboxyl group in RGD or LDV has
led to the suggestion that it participates in a direct coordi-
nation with the integrin-bound cation. Clearly, a ligand–
integrin co-crystal is needed to determine the validity of
this prediction.
α αA-domain-containing integrins
In contrast to the aforementioned situation with non-αA-
domain-containing integrins, the major ligand-binding site
within those integrins that contain an αA-domain is clearly
found within the 200-amino-acid polypeptide module that
is inserted within the α-subunit β-propeller. A variety of evi-
dence supports this conclusion, including the mapping of
antifunctional mAbs to the αA-domain, the ability of the
isolated domain to bind ligand, the inhibitory effects of
mutations within the αA-domain on ligand binding, and,
most recently, the resolution of the tertiary structure of an
αA-domain–ligand complex.
Recombinant αA-domains
In solid-phase assays, the αM A-domain was found to bind
to its ligands iC3b, intercellular adhesion molecule
(ICAM)-1, ICAM-2, and fibrinogen in a divalent cation-
dependent manner [31,32]. The αL A-domain similarly
bound directly to purified recombinant ICAM-1 and also
inhibited αLβ2-dependent T-cell adhesion to ICAM-1 [33].
The A-domains from α1 and α2 were found to bind to a
variety of collagen isotypes, including types I and IV, and
laminin in a cation-dependent manner [34–36]. Finally, the
αD A-domain has been shown to contain a binding site for
vascular cell adhesion molecule-1 [37].
α αA-domain mutagenesis and chimeras
Inter-integrin chimeras have proven useful to map ligand-
binding sites within αA-domains. Since mouse αLβ2 does
not bind human ICAM-1, interspecies chimeras were con-
structed to identify the ligand-binding regions [38].
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Replacement of two noncontiguous regions in the A-
domain (residues 119–153 and 218–248) abolished
binding. Key residues were found to be M140, E146,
T243, and S245, which are located around the cation-
binding site. In complementary studies, data from a large
number of site-directed mutagenesis experiments, the
results of which are summarised in [29], have suggested
residues that are critical for interaction of αA-domains with
ligands. In addition to cation-coordinating residues, which
are essential for the function of all αA-domains, sites
within the α3–α4 and βD–α5 loops are frequently impli-
cated. Both loops are located on the top, cation-binding
face of the αA-domain.
mAb epitope mapping
Recombinant A-domains of α1, α2, αL, αM, αX and αD
have now been shown to contain the epitopes for antifunc-
tional anti-α-subunit mAbs, and interspecies and inter-inte-
grin chimeras have been used to localise antifunctional mAb
epitopes to αA-domains. For example, three distinct epi-
topes within residues 126–150 of the αL A-domain, which
is a region close to the cation-binding site, were identified
using human–mouse point chimeras [39]. Also, the epitope
of anti-α1 mAb AJH10 was localised to the loop between
the α3 and α4 helices, which again contributes one of the
metal coordination sites of the A-domain [40].
Integrin–ligand co-crystal
Many of these predictions were confirmed in an important
study where the crystal structure of a complex between
the α2 A-domain and a triple-helical collagen peptide con-
taining a critical GFOGER motif was determined [41].
Three loops on the upper surface of the α2 A-domain that
coordinate the cation were found to engage the collagen,
with a glutamate residue from the collagen completing the
coordination sphere of the metal, and an arginine residue
from the same strand of the collagen helix bridging to
D219 in the α3–α4 loop on top of the A-domain (Fig. 2).
Two phenylalanine residues, one in the same collagen
strand as the arginine residue and one in the trailing
strand, made further contacts. Hydrogen bonds between
the collagen main chain and N154, Y157 (βA–α1 loop)
and H258 (βD–α5 loop) of the A-domain were seen.
The use of the glutamate residue for cation coordination sug-
gests that the same mechanism may be employed by other
integrin ligands to bind to αA-domains, and it also gives a
snapshot of how aspartate-containing ligands may bind to
βA-domains in those integrins that lack an αA-domain.
Integrin activation
For the interaction of integrins with their ligands to be mean-
ingful for cellular function, the binding event must be able to
trigger signal transduction. In part this will be accomplished
by ligands inducing conformational changes in integrins that
create effector binding sites and/or exposure of sites to
modifying enzymes. Following the solution of the αVβ3
crystal structure, it is possible to place information that has
accumulated from a plethora of studies on integrin activa-
tion into a structural context. The long-term aims of this work
are to elucidate the structural link between ligand binding
and signalling, and to develop strategies for interfering ther-
apeutically in the activation process.
Conformational changes mediating activation
Gross conformational changes in integrins have been
detected by a variety of techniques. For almost all of these
studies, αIIbβ3 has served as a prototype. For example,
treatment of αIIbβ3 with ligand peptides increased its
hydrolysis by thrombin and decreased its sedimentation
coefficient [42], and platelet activation caused a change in
the spatial separation or orientation of the extracellular
domains of the two subunits as measured by fluorescence
resonance energy transfer [43].
Much work has been carried out on activation-dependent
binding of mAbs to integrins, some of which have been
called ligand-induced binding sites (LIBS) [44]. Binding of
cyclic mimics of different ligand peptides to αIIbβ3 in
intact platelets was recently found to trigger distinct con-
formational alterations in the receptor, as indicated by the
differential exposure of LIBS epitopes [45]. This suggests
that different ligands may initiate different functional con-
sequences within the receptor. The changes reported by
mAbs can be triggered not only from the extracellular side
of the integrin in response to ligand binding, but also from
the cytoplasmic side of the plasma membrane, suggesting
that conformational regulation is an important feature of
bidirectional signalling by integrins [46].
Mechanisms of conformational change causing
activation
Activation via the αA-domain
As already described, the first crystal structures of the αA-
domain, solved for Mg2+-occupied and Mn2+-occupied
forms of the αM domain, revealed different structures
[14,15]. A comparative analysis revealed a change in
metal coordination, a large (10 Å) shift of the C-terminal
α7 helix, and the solvent exposure of F302. It was sug-
gested that the movement of the α7 helix in the context of
the intact integrin might induce further conformational
changes outside of the αA-domain.
Comparison of the tertiary structure of the α2 A-
domain–collagen peptide complex with the unoccupied α2
A-domain structure [41,47] revealed similar changes that
provide insight into the process of receptor activation
(Fig. 2). The central β-sheet did not change appreciably in
the two structures, but there were significant changes in
cation coordination and helix organisation. A 2.6 Å move-
ment of the cation resulted in the formation of a direct bond
with T221 (this residue coordinated via a water molecule in
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the unoccupied structure), a loss of coordination to D254,
and a new coordination to E256. This reorganisation of the
upper surface of the A-domain reoriented the side chains
of Y157 and H258 such that they were able to fit into
grooves in the collagen helix. The shifts in the positions of
cation-coordinating loops triggered a rearrangement of the
α7 and C helices, the former moving away and down by
10 Å and the latter unwinding. As a consequence of these
movements, Y285 in the C helix moved 17 Å and hydrogen
bonded with the repositioned α7 helix.
The relevance of the large movement of the α7 helix in
both the αM and α2 structures as a consequence of
ligand engagement is as yet unclear, but since this
sequence is at the C-terminus of the αA-domain, and is
therefore connected to the remainder of the subunit, it is
tempting to speculate that the conformational change will
be propagated through the receptor to initiate signalling. A
key question is how the α7 helix contacts the remainder of
the integrin, and in particular whether it interacts with the
βA-domain to alter its conformation (i.e. whether a ligand-
binding event in the αA-domain can have a similar effect to
direct ligand binding at the βA-domain).
Activation in non-αA-domain-containing integrins
In contrast to the situation with αA-domain-containing
integrins, little is currently known about the intramolecular
activation of non-αA-domain-containing integrins. If the
ligand-responsive subset of activating mAbs recognises
sites that occur naturally in integrins, the location of their
epitopes will inform an understanding of the process of
receptor activation.
A large number of studies have thus pinpointed activating
mAb epitopes by mutagenesis and the use of interspecies
integrin chimeras, and these can now be placed in the
context of the crystal structure. The overwhelming majority
of activating mAbs recognise the β-subunit and, interest-
ingly, while their epitopes are distributed throughout the
polypeptide, suggesting large-scale alteration in the con-
formation of the whole integrin during activation, a number
of specific regions appear to be recognised. These
regions include the extreme N-terminus of the β-subunit in
the PSI domain [48], the βA-domain [49], the hybrid
domain [50], and the epidermal growth factor repeats
[51,52]. The α1 and α2 helices of the βA-domain, in par-
ticular, contain the epitopes for a large number of mAbs,
some of which were function blocking and others of which
were stimulatory for ligand binding [49]. As these ele-
ments are linked to the cation-binding site in the βA-
domain, it is conceivable that ligand binding triggers an
alteration in their positioning, and that this change is then
propagated to the rest of the integrin.
Integrins are relatively large receptors, and a major challenge
is to understand how proximal conformational changes in the
ligand-binding pocket are passed to the rest of the integrin,
and ultimately to the cytoplasmic domains. As there is cur-
rently little direct information to inform these issues, any theo-
ries will be highly speculative. There is evidence, based on
competitive ELISA experiments, that the domains of the α5-
subunit and the β1-subunit recognised by mAb JBS5/16
(anti-α5) and mAb 13/12G10 (anti-β1) are spatially close,
and that the distance between these two domains increased
when α5β1 was occupied by divalent cations [53]. This sug-
gested that divalent cations induced a conformational relax-
ation in the integrin that resulted in exposure of
ligand-binding sites, and that these sites were located near
to the interface between the α-subunit and the β-subunit.
The structural homology between the integrin head and
heterotrimeric G-proteins would also be consistent with a
conformational repositioning of these regions of the recep-
tor [1]. The bending of the legs in the αVβ3 crystal struc-
ture, whether a true indication of the native structure of the
integrin or a crystallisation artifact, suggests that there are
sites in both subunits that exhibit extreme flexibility. While
this suggests that the head of the integrin may pivot
around the α-subunit thigh–calf junction and the β-subunit
hybrid–epidermal growth factor–PSI linkage, it also raises
questions about how shape changes induced by ligand
binding are able to pass two flexible joints. By constraining
the relative position of the membrane-proximal domains of
integrin αLβ2 with coiled-coil extensions, it was found that
the integrin could be inactivated by bringing its legs close
together (with an acid–base coiled coil) and could be acti-
vated by keeping them apart (with a base–base extension)
[54]. Similarly, proteolytic cleavage of a constrained inte-
grin had the same activating effect [55]. This suggests
that a gross repositioning of the legs and cytoplasmic
domains underlies integrin activation.
Role of cation-binding sites
The binding of ligands to integrins is universally divalent
cation dependent, and occupancy by different cations
results in different levels of ligand binding. It is therefore
important to consider the location, specificity and func-
tional role of cation-binding sites. Integrin-ligand binding is
usually stimulated by Mg2+ and Mn2+, and inhibited by
Ca2+, as shown first for α5β1 [56]. In the αVβ3 crystal
structure, six Ca2+-binding sites are seen (Fig. 1). Four of
these lie in β–loop–β structures on the lower face of the β-
propeller, and another site is the knee region of the α-
subunit. The top face of the βA-domain contains a
potential cation-binding site, known as the metal-ion
dependent adhesion site (MIDAS), although this is unoc-
cupied in the crystal structure. A novel site is seen adja-
cent to the MIDAS, however, which the authors termed
‘adjacent to MIDAS’ (ADMIDAS).
The functional role of the different cation binding sites is
discussed later. Apart from their occupancy in the crystal
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structure, the most convincing evidence that the EF-hand-
like sequences in the β-propeller bind calcium derives
from the fact that the epitope for Ca2+-dependent mAb
CBRM1/20 has been localised to the EF-hand-like
sequence in repeat 5 of αM [57].
Crystal structures of αA-domains have proven the pres-
ence of a cation-binding site in this module. A characteris-
tic ‘DXSXS’ motif (D140GSGS in αM) located at the
junction of the βA strand and the loop between βA and α1
was found to contribute three of these coordination sites:
D140 via a water molecule, and S142 and S144 directly.
Two sequentially distant residues, T209 at the C-terminal
end of the α3–α4 loop and D242 at the start of the
βD–α5 loop, also coordinated, the former directly and the
latter via water. Given the sequence and functional homol-
ogy between the A-domains in both subunits, a similar
motif is also highly likely to be found in βA-domains.
However, the fact that the crystals were grown in calcium
may explain the lack of occupancy.
Until further crystal forms are obtained, it is not clear
where Mn2+ and Mg2+  bind within integrins. However,
there is much biochemical evidence to suggest sites.
Using the interaction between α5β1 and fibronectin as a
model system, a comprehensive analysis of the effects of
Mn2+, Mg2+, and Ca2+ on ligand binding was carried out
[58]. Each cation had distinct effects on ligand-binding
capacity: Mn2+ promoted high levels of ligand binding,
Mg2+ promoted low levels of binding, and Ca2+ failed to
support binding. Ca2+ strongly inhibited Mn2+-supported
ligand binding, but this inhibition was noncompetitive,
suggesting that Ca2+ recognises different cation-binding
sites to Mn2+. In contrast, Ca2+ acted as a direct competi-
tive inhibitor of Mg2+-supported ligand binding, implying
that Ca2+ can displace Mg2+ from the integrin. However,
low concentrations of Ca2+ greatly increased the apparent
affinity of Mg2+ for its binding site, suggesting the exis-
tence of a distinct high-affinity Ca2+-binding site.
In summary, evidence is accumulating to suggest that non-
αA-domain-containing integrins generally contain a cation-
binding site that is required for ligand binding and that
interacts with Mg2+, Mn2+ (to promote binding) or Ca2+ (in
which case binding does not occur). In addition, occu-
pancy of a separate calcium-binding site, or class of sites,
can enhance ligand binding in an allosteric, synergistic
manner. The location of the different sites is not yet
defined, although it is likely that the Mg2+/Mn2+/Ca2+-
binding site is the MIDAS site in the βA-domain. The role
of the ADMIDAS site is currently unclear, although it may
be an inhibitory Ca2+-binding site [59].
An interesting feature of some LIBS mAbs is that their epi-
topes are also regulated by divalent cations (for example
[53,60]). Since cations also regulate ligand binding, and in
some cases the pattern of effects by different cations is
the same for mAb and ligand binding [53], it appears that
some activating mAbs recognise sites that are regulated
by natural modulators of integrin function. One possibility
is that cation-responsive activating mAbs recognise natu-
rally occurring conformers of integrins.
Cation effects on integrin conformation have been reported
to vary between dimers. Mn2+ or ligand induced 9EG7 or
15/7 binding strongly on α4β1, moderately on α5β1,
weakly on α2β1, and undetectably on α3β1 and α6β1
[61]. Ca2+ uniquely supported constitutive expression of
the 9EG7 epitope on α4β1. Thus, not all LIBS mAbs will
be faithful reporters of occupancy.
Finally, the different properties of activating antibodies
imply that care should be taken in using them as probes of
integrin function. It is probable that different mAbs will sta-
bilise different integrin conformers and, if so, the conse-
quences for signalling may also differ.
Concluding remarks
Now that the feasibility of generating a crystal structure of
an integrin is proven, many other structural questions can
be asked. Key targets for future crystallography studies
include different integrin conformers representing different
activation states, ligand-occupied integrins, and integrins
containing an αA-domain.
Although, as already described, the general location of the
ligand-binding pocket of an integrin can now be predicted,
the atomic detail will require an integrin–ligand co-crystal.
Once this is achieved, the process of drug development
based on ligand mimetics will be aided. Interestingly, the
allosteric inhibition of ligand binding by antifunctional anti-
integrin mAbs implies that it may be feasible to synthesise
small molecule inhibitors that function in the same way.
Such inhibitors may not possess the agonistic properties
of ligand mimetics, and may therefore not suffer from
mechanism-related side effects.
As yet, the generation of allosteric integrin inhibitors is in
its infancy, although a recent report of the tertiary struc-
ture of the αL A-domain in complex with lovastatin has
provided an insight into such a mode of action. Statins
are drugs used clinically for lowering cholesterol levels,
but they are also reported to inhibit the interaction of
αLβ2 with ICAM-1 [62,63]. Using nuclear magnetic reso-
nance spectroscopy and X-ray crystallography, the
inhibitor was shown to bind to the αL A-domain in a
crevice between the central β-sheet and the C-terminal
α7 helix. This finding suggests that the inhibitor may func-
tion by preventing movement of α7 relative to the rest of
the domain and preventing subsequent intramolecular
conformational changes [64]. It is possible that a similar
approach may be used to develop allosteric inhibitors of
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the βA-domain, and that this may spawn a new genera-
tion of anti-adhesive drugs.
Glossary of terms
ADMIDAS = adjacent to metal ion-dependent adhesion
site; LIBS = ligand-induced binding site; MIDAS = metal
ion-dependent adhesion site; PSI = plexin–semaphorin–
integrin.
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